Coverage
-
April 03, 2017
Israeli biotech company Enzymotec Ltd. and a putative class of shareholders have reached a $6.5 million settlement and asked a New Jersey federal judge on Friday to recognize the class and give the deal preliminary approval.
3 other articles on this case.
View all »